-
公开(公告)号：US20080242725A1
公开(公告)日：2008-10-02
申请号：US10590780
申请日：2005-02-28
申请人： Janez Kerc , Peter Svete , Zdenka Jerala-Strukelj , Vlasta Humar , Rok Grahek , Breda Husu-Kovacevic
发明人： Janez Kerc , Peter Svete , Zdenka Jerala-Strukelj , Vlasta Humar , Rok Grahek , Breda Husu-Kovacevic
IPC分类号： A61K31/225 , A61K47/26 , A61P9/10
CPC分类号： A61K9/1652 , A61K31/4184 , A61K31/695 , C07C67/62 , C07C2602/28 , C07C69/33
摘要： Stabilized pharmaceutical compositions comprising polymorphs of active pharmaceutical ingredients susceptible to conversion to alternate polymorph forms are prepared by a process of wet granulation in which the ratios of active, fillers, and granulating liquid are controlled in order to avoid polymorphic interconversions.
摘要翻译： 包含易于转化为交替多晶型形式的活性药物成分的多晶型物的稳定化药物组合物是通过湿法制粒方法制备的，其中控制活性成分，填充剂和制粒液体的比例以避免多晶型相互转化。
-
公开(公告)号：US20070298108A1
公开(公告)日：2007-12-27
申请号：US10590889
申请日：2005-02-28
CPC分类号： A61K9/28 , A61K31/4184 , A61K31/695 , C07D403/10
摘要： Composition were developed which stabilize an active pharmaceutical ingredient in polymorph form susceptible to degradation or interconversion into other polymorph forms, where stabilizing substance is conveniently among silicon dioxide, silicified microcrystalline cellulose, magnesium oxide and polyethylene glycol.
摘要翻译： 开发了将多晶型形式的活性药物成分稳定化的组合物，其易于降解或相互转化为其它多晶型物，其中稳定物质方便地在二氧化硅，硅化微晶纤维素，氧化镁和聚乙二醇中。
-
3.发明授权Preparation of new pharmaceutically suitable salt of losartan and forms thereof with new purification and isolation methods 失效用新的纯化和分离方法制备新的药物合适的氯沙坦盐及其形式公开(公告)号：US07271269B2
公开(公告)日：2007-09-18
申请号：US10524993
申请日：2004-01-29
申请人： Ljubomir Antoncic , Anton Copar , Peter Svete , Breda Husu-Kovacevic , Zoran Ham , Boris Marolt
发明人： Ljubomir Antoncic , Anton Copar , Peter Svete , Breda Husu-Kovacevic , Zoran Ham , Boris Marolt
IPC分类号： C07D257/04
CPC分类号： C07D403/10
摘要： Pharmaceutically suitable crystalline and amorphous alkali and earth-alkali salts of 2-n-butyl-4-chloro-5-hidrox-ymethyl-1-[[2′-(1 H-tetrazole-5-yl)[1.1′-biphenyl]-4-yl]-1 Himidazole have been prepared and new manufacturing, purification and isolation procedure for said salts in high purity have been described. Stable pharmaceutical compositions containing new crystalline potassium salts of 2-n-butyl-5-chloro-5hidroxymethyl-1-[[2′-(1H-tetrazole-5-yl)[1.1′-biphenyl]-44-yl]-1H-imidazole have been prepared.
摘要翻译： 2-正丁基-4-氯-5-羟基甲基-1 - [[2' - （1H-四唑-5-基）[1.1'-联苯]的药学上合适的结晶和无定形碱金属和碱土金属盐 ] -4-基] -1H-咪唑，并描述了高纯度的所述盐的新的制备，纯化和分离程序。 含有2-正丁基-5-氯-5-羟基甲基-1 - [[2' - （1H-四唑-5-基）[1.1'-联苯] -44-基] -1H的新结晶钾盐的稳定药物组合物 咪唑制备。
-
4.发明申请Preparation of new pharmaceutically suitable salt of losartan and forms thereof with new purification and isolation methods 失效用新的纯化和分离方法制备新的药物合适的氯沙坦盐及其形式公开(公告)号：US20060004207A1
公开(公告)日：2006-01-05
申请号：US10524993
申请日：2004-01-29
申请人： Ljubomir Antoncic , Anton Copar , Peter Svete , Breda Husu-Kovacevic , Zoran Ham , Boris Marolt
发明人： Ljubomir Antoncic , Anton Copar , Peter Svete , Breda Husu-Kovacevic , Zoran Ham , Boris Marolt
IPC分类号： C07D403/02 , A61K31/4184
CPC分类号： C07D403/10
摘要： Pharmaceutically suitable crystalline and amorphous alkali and earth-alkali salts of 2-n-butyl-4-chloro-5-hidrox-ymethyl-1-[[2′-(1H-tetrazole-5-yl)[1.1′-biphenyl]-4-yl]-1 Himidazole have been prepared and new manufacturing, purification and isolation procedure for said salts in high purity have been described. Stable pharmaceutical compositions containing new crystalline potassium salts of 2-n-butyl-5-chloro-5hidroxymethyl-1-[[2′-(1H-tetrazole-5-yl)[1.1′-biphenyl]-44-yl]-1H-imidazole have been prepared.
摘要翻译： 2-正丁基-4-氯-5-羟基甲基-1 - [[2' - （1H-四唑-5-基）[1.1'-联苯]]酮的药学上合适的结晶和无定形碱金属和碱土金属盐， -4-基] -1H咪唑，并描述了高纯度的所述盐的新的制备，纯化和分离程序。 含有2-正丁基-5-氯-5-羟基甲基-1 - [[2' - （1H-四唑-5-基）[1.1'-联苯] -44-基] -1H的新结晶钾盐的稳定药物组合物 咪唑制备。
-
公开(公告)号：US20100034887A1
公开(公告)日：2010-02-11
申请号：US12086657
申请日：2006-12-21
申请人： Polonca Kuhar , Peter Svete , Judita Sirca
发明人： Polonca Kuhar , Peter Svete , Judita Sirca
IPC分类号： A61K9/14 , A61K31/415 , A61P19/02
CPC分类号： A61K9/1652 , A61K9/1617 , A61K9/1623 , A61K31/415
摘要： In the present invention, a new pharmaceutical formulation of bursting pellets comprising in the core a high dose of a low potency active substance which is poorly soluble in water is described. Release of the active substance from the core takes place within minutes.
摘要翻译： 在本发明中，描述了一种爆炸性丸剂的新药物制剂，其在核心中含有高剂量的低溶性活性物质，其水溶性差。 活性物质从核心的释放发生在几分钟之内。
-
公开(公告)号：US20100120868A1
公开(公告)日：2010-05-13
申请号：US12613775
申请日：2009-11-06
IPC分类号： A61K31/4439 , A61P3/10
CPC分类号： A61K9/5084 , A61K9/1623 , A61K9/1652 , A61K9/167 , A61K9/2077 , A61K31/4439 , A61K31/64 , A61K45/06 , A61K2300/00
摘要： The invention relates to a process for preparing a solid pharmaceutical composition rosiglitazone maleate, comprising the step of adsorption of rosiglitazone maleate onto carrier particles (C) during a dry mixing process.
摘要翻译： 本发明涉及制备固体药物组合物马来酸罗格列酮的方法，其包括在干混合过程中将马来酸罗格列酮吸附到载体颗粒（C）上的步骤。
-
公开(公告)号：US20090136578A1
公开(公告)日：2009-05-28
申请号：US11991201
申请日：2006-08-28
申请人： Peter Svete
发明人： Peter Svete
IPC分类号： A61K9/14 , A61K31/403
CPC分类号： A61K9/2054 , A61K9/14 , A61K9/2009 , A61K31/404
摘要： The present invention relates to a stable pharmaceutical composition of the ACE inhibitor perindopril or its salts having a defined particle size distribution.
摘要翻译： 本发明涉及具有确定的粒度分布的ACE抑制剂培哚普罗或其盐的稳定药物组合物。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.042 秒)
